miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1

BACKGROUND: Treatment options for metastatic castrate-resistant prostate cancer (mCRPC) are limited and typically are centered on docetaxel-based chemotherapy. We previously reported that elevated miR-375 levels were significantly associated with poor overall survival of mCRPC patients. In this stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuan, Lieberman, Rachel, Pan, Jing, Zhang, Qi, Du, Meijun, Zhang, Peng, Nevalainen, Marja, Kohli, Manish, Shenoy, Niraj K., Meng, Hui, You, Ming, Wang, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5105253/
https://www.ncbi.nlm.nih.gov/pubmed/27832783
http://dx.doi.org/10.1186/s12943-016-0556-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5105253/
https://www.ncbi.nlm.nih.gov/pubmed/27832783
http://dx.doi.org/10.1186/s12943-016-0556-9

Ejemplares similares